Medication patches are available in a limited number of dosage strengths. Occasionally, some patients require a different dosage of a medication than the dosages commercially available in patch form.
Nutriband initiates commercial worldwide brand name development for its lead product, an abuse deterrent transdermal system. Nutriband has ...
1d
Nutriband Files Provisional Patent Application for Enhanced Transdermal Abuse Deterrent Technology
Nutriband files provisional patent application to enhance its AVERSA™ transdermal abuse deterrent technology being developed for patches containing opioids and stimulants with a potential for abuse.
Built on the company's now-patented innovations, Ategenos SmartPatches contain reformulated oral solid dose (OSD) blockbuster drugs in a connected, transdermal SmartPatch that delivers ...
ALTO-101 is an investigational phosphodiesterase-4 (PDE4) inhibitor delivered via a transdermal patch. Inhibition of the PDE4 enzyme is expected to enhance neural circuits and improve cognitive ...
The Subject Expert Committee (SEC - Oncology) under the Central Drugs Standard Control Organization (CDSCO) has requested ...
For a number of reasons, it may be helpful to write on a patch after it is applied to the patient. For example, some TDDS products are formulated as a clear patch so they are less noticeable, which is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback